Want to see INKT full AI Analyst Report?
INKT Stock Chart & Stats
$11.07
$0.71(6.85%)
At close: 4:00 PM EDT
$11.07
$0.71(6.85%)
Day’s Range― - ―
52-Week Range$8.48 - $16.98
Previous CloseN/A
Volume20.36K
Average Volume (3M)39.56K
Market Cap
$62.26M
Enterprise Value$49.92
Total Cash (Recent Filing)$8.81B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.03
Next Earnings
Nov 13, 2026EPS Estimate
-0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.39
Shares Outstanding5,103,002
10 Day Avg. Volume31,712
30 Day Avg. Volume39,559
Financial Highlights & Ratios
PEG Ratio-3.68
Price to Book (P/B)-3.35
Price to Sales (P/S)0.00
P/FCF Ratio-8.04
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$35.00Price Target Upside216.17% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.75
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Off-the-shelf INKT PlatformAn inventory-based, allogeneic product could simplify deployment, reduce manufacturing complexity, and broaden access versus personalized cell therapies. The platform's use in austere settings may support scalability across cancer and serious-disease indications.
Randomized Phase 2 ExecutionMoving from early observations into a randomized study is a meaningful development milestone. Comparative data targeted for early 2027 can clarify efficacy and potentially support a seamless Phase 3 pathway, strengthening the program's development credibility.
Improving Loss TrendNarrower quarterly and year-to-date losses indicate some operating discipline while clinical development advances. Continued cost control would extend resources and reduce the rate at which capital is consumed, although the company remains pre-revenue.
Bears Say
No Revenue And Persistent LossesMiNK has not established commercial revenue and remains materially loss-making, with negative gross profit across periods. Without an approved product or recurring inflows, future progress depends on successful clinical development and eventual external financing.
Severe Cash-flow RiskPersistent cash burn limits financial self-sufficiency and creates funding risk as trials expand. The exceptionally large reported TTM operating outflow relative to historical scale further reduces confidence in the current capital base supporting development without new funding.
Early Efficacy And Trial UncertaintyPromising early observations cannot yet demonstrate treatment benefit because they come from a limited, non-randomized cohort. Enrollment, population differences, placebo design, FDA discussions, and endpoint changes could affect trial power, timing, and eventual approval prospects.
MiNK Therapeutics News
INKT FAQ
What was MiNK Therapeutics’s price range in the past 12 months?
MiNK Therapeutics lowest stock price was $8.48 and its highest was $16.98 in the past 12 months.
What is MiNK Therapeutics’s market cap?
MiNK Therapeutics’s market cap is $62.26M.
When is MiNK Therapeutics’s upcoming earnings report date?
MiNK Therapeutics’s upcoming earnings report date is Nov 13, 2026 which is in 80 days.
How were MiNK Therapeutics’s earnings last quarter?
MiNK Therapeutics released its earnings results on Aug 13, 2026. The company reported -$0.62 earnings per share for the quarter, missing the consensus estimate of -$0.6 by -$0.02.
Is MiNK Therapeutics overvalued?
According to Wall Street analysts MiNK Therapeutics’s price is currently Undervalued.
Does MiNK Therapeutics pay dividends?
MiNK Therapeutics does not currently pay dividends.
What is MiNK Therapeutics’s EPS estimate?
MiNK Therapeutics’s EPS estimate is -0.35.
How many shares outstanding does MiNK Therapeutics have?
MiNK Therapeutics has 5,103,002 shares outstanding.
What happened to MiNK Therapeutics’s price movement after its last earnings report?
MiNK Therapeutics reported an EPS of -$0.62 in its last earnings report, missing expectations of -$0.6. Following the earnings report the stock price went down -3.169%.
Which hedge fund is a major shareholder of MiNK Therapeutics?
Currently, no hedge funds are holding shares in INKT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MiNK Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$35.00 (216.17% Upside)
$35.00 (216.17% Upside)
Hedge Fund Trend
Decreased
By 3.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $19.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.3%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
108.86%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
287.02%
Trailing 12-Months
Company Description
MiNK Therapeutics
MiNK Therapeutics, Inc. is a biopharmaceutical firm currently undergoing clinical trials. Its primary focus is on the identification, advancement, and market introduction of innovative invariant natural killer T (iNKT) cell therapies. These treatments are allogeneic and designed to be "off-the-shelf," providing readily available options for combating various cancers and conditions rooted in immune system dysfunction. The company's leading investigational therapy is AGENT-797. This product is an allogeneic, ready-to-use iNKT cell therapy, presently in Phase 1 clinical studies to assess its effectiveness against different forms of myeloma. Established in 2017, the company was previously known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. is headquartered in New York, New York, and operates as a subsidiary of Agenus Inc.
INKT Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call delivered several important operational and scientific advances: initiation and operationalization of a randomized Phase 2 ARDS study (including dosing in an active conflict zone), positive early clinical and mechanistic signals from run-in patients, launch of a paid international named patient access program (Brazil), and improved quarter-over-quarter loss metrics. However, early clinical data are limited and non-randomized, operating cash usage increased (cash modestly declined q/q to $8.8M), and enrollment/regulatory risks and funding needs remain. On balance, the call emphasized meaningful progress on execution and translational rationale while acknowledging remaining proof-of-concept and financing risks.View all INKT earnings summariesINKT Stock 12 Month Forecast
Average Price Target
$35.00
▲(216.17% Upside)
Technical Analysis
Ownership Overview
4.68% Insiders
1.40% Mutual Funds
1.43% Other Institutional Investors
91.02% Public Companies and
Individual Investors